Effect of codeine phosphate, Lomotil, and Isogel on iileostomy function.
The effect on ileostomy function of codeine phosphate, Lomotil, or Isogel was tested in 20 subjects at home living a normal life, studied over two three-day periods on and off treatment. Codeine phosphate 60 mg three times daily was associated with a reduction in the mean total weight of ileostomy output and the ileostomy outputs of water, sodium, and potassium (p < 0.05). The proportion of faecal solids increased on codeine and the effluent appeared thicker but the output of faecal solids remained unchanged. Mean faecal fat increased on codeine. The transit rate from mouth to stoma was slower in four of the five subjects on codeine and a further two subjects withdrew from the trial with temporary intestinal obstruction while on the drug. Lomotil two tablets three times daily was associated with a small and statistically not quite significant fall in the mean total weight of ileostomy output and the ileostomy output of water. Sodium and potassium outputs in the effluent fell on Lomotil (p < 0.05) but the other parameters remained unchanged. Isogel 15 ml three times daily was associated with an increase in the mean total weight of ileostomy output and the ileostomy outputs of water, sodium, potassium, and faecal solids (p < 0.01). Although the effluent looked more viscid on Isogel, the proportion of faecal solids was unchanged. These results suggest that codeine phosphate has a beneficial effect on ileostomy function, reducing the loss of water and electrolytes, while Lomotil has a similar but less effective action in the dosage tested. By contrast, Isogel increases the ileostomy loss of water and electrolytes and will aggravate their depletion in patients with excessive fluid effluents. The increase in faecal fat associated with taking codeine phosphate suggests that it should be stopped before collecting specimens for faecal fat estimations.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001285:Atropine / Q000627:therapeutic use*; D003061:Codeine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003967:Diarrhea / Q000188:drug therapy*; D004157:Diphenoxylate / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D007081:Ileostomy; D007540:Isonipecotic Acids / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy*; D011620:Psyllium / Q000627:therapeutic use*
D004338:Drug Combinations; D007540:Isonipecotic Acids; D004157:Diphenoxylate; D001285:Atropine; D011620:Psyllium; D003061:Codeine